Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT04918810 is registered in ClinicalTrials.gov with Australian and New Zealand Urogenital and Prostate Cancer Trials Group as lead sponsor.

NCT NCT04918810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04918810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Lead sponsor
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase
Phase 2
Overall status
Terminated
Start date
July 29, 2022
Completion date
November 1, 2024
Enrollment
6 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

castration resistant prostatic cancer